Ace Blend Bets on Clinical Proof With a 95 Crore Nutrition Push
Posted on 29th Oct 2026 11:08:13 in Business, Digital Marketing
Tagged as: D2C nutrition, dietary supplements, Ace Blend, 3one4 Capital, nutraceutical India, D2C funding
Ace Blend has raised $9.91 million, roughly Rs 95 crore, in a Series A2 round led by 3one4 Capital, with existing investor Fireside Ventures putting in more money. On the surface it is one more funding announcement in a busy week for Indian consumer brands. The interesting part is what the money is for.
The Mumbai-based nutrition and dietary supplements brand is not spending the round on performance marketing. According to founder Shivam Hingorani, the capital goes into clinical trials run by contract research organisations, tighter control over ingredient sourcing and manufacturing, batch-level product testing, and consumer education. That is an unusual list for a direct-to-consumer brand in India, where most growth capital still goes into ad platforms, discounting and marketplace placement.
For small sellers in the supplements and wellness space, the round is worth reading closely. It lays out, in public, the four problems that break nutrition brands as they scale: proof, supply chain, batch consistency and trust. Each of those problems arrives whether or not a brand has venture money to solve it.
Why This Round Is Not an Advertising Budget
Ace Blend was founded in 2018 by Hingorani, with Saif Mehkri joining as co-founder in 2022. It sells about 14 stock-keeping units across heart health, brain health, sleep, recovery, gut health, strength and immunity, including plant-based protein powders, superfood mixes and functional supplements. The company works with global ingredient suppliers such as DSM-Firmenich and says it holds exclusive India rights to certain ingredient technologies.
The first use of funds is clinical research. Ace Blend intends to run trials with internationally reputed contract research organisations and publish the findings in international journals. The company has already completed a study on an inflammation-focused formulation that combines black nigella seed oil extract, thymoquinone, curcumin extract and medium-chain triglyceride oil, with the aim of reducing inflammatory markers over 12 to 14 weeks.
Hingorani draws a sharp line between borrowing science and building it. "We are not science-backed. We are science-built," he told ETEntrepreneur, describing an approach built from the ground up on pharmacokinetic studies and clinical trials rather than on published research attached to ingredients bought off the shelf. He called the intent "the rigour of a pharmaceutical company brought to the nutraceutical segment."
That distinction matters commercially. In a category where dozens of brands sell the same imported ingredients with different labels, a published trial is one of the few claims a competitor cannot copy in a week. It is also expensive, slow and unglamorous, which is precisely why it functions as a moat.
The Repeat Purchase Number Behind the Cheque
The number that makes the rest of the strategy legible is retention. Ace Blend says more than 46 per cent of its customers come back to buy again. Indian Retailer put the repeat purchase rate at close to 48 per cent, and reported that the company grew 300 per cent in FY26.
In supplements, repeat purchase is the whole business model. A protein powder or a sleep formulation is a consumable with a defined cycle, so a customer who buys once and never returns is a loss dressed up as revenue. A brand converting nearly half its buyers into repeat buyers has a predictable base to spend against, which is what allows it to chase the stated target of Rs 250-300 crore in annual recurring revenue over the next 12 to 18 months while keeping profitability in the plan.
The company's earlier trajectory shows how fast that base compounds. When Fireside led a $3.3 million pre-Series A round in August 2025, Ace Blend had grown from Rs 1.9 crore in revenue to a projected Rs 55 crore over three years, with 250 per cent growth in the first year and a near doubling in the second.
For smaller sellers, the lesson is not the round size. It is the metric. Most D2C dashboards track spend, click-through rate and return on ad spend; very few track the share of customers who order a second time within 90 days, split by the channel that acquired them. That single cohort number tells a seller whether the ads are buying customers or buying transactions.
Quality Control as the Moat: The Third-Batch Problem
The second and third uses of the capital are supply chain integration and testing, and this is where the founder's description gets uncomfortably specific for anyone who has used contract manufacturers.
"By the time the third batch happens, a nutraceutical company that is primarily a marketing company today can lose track of how quality starts to dip," Hingorani said. "We want to prevent that for the lifetime of the brand."
At low volumes, a brand can ride on a supplier's consistency and never notice. As volumes grow and sourcing spreads across countries, small formulation drifts show up as taste changes, texture changes and, worse, potency changes. Ace Blend is responding by building a vertically integrated operation covering ingredient sourcing, formulation and manufacturing, and by putting in a testing system that checks nutritional accuracy, pesticide residues and heavy metals batch by batch, with the aim of removing human intervention from the process.
The company also plans shelf-stability studies at launch and again six months later. That is a quietly important detail. A supplement can sit in a distributor's warehouse and on a marketplace shelf for months before a customer opens it, so a product that passed at the point of manufacture may not meet its label claim at the point of use. Testing only at production measures the wrong moment.
Hingorani's summary of the problem is blunt: "Trust is not enough."
Doctors, Quick Commerce and a Mixed Channel
Ace Blend's revenue is split between its own website, marketplaces and quick commerce. The company puts direct-to-consumer sales at roughly 45 to 50 per cent of the business, with the website alone contributing around half of revenue, and the rest coming from Amazon, Flipkart, Zepto, Blinkit and other channels.
The unusual part of the distribution mix is the professional channel: more than 400 doctors actively recommend its products. Rather than hiring conventional medical representatives, Ace Blend employs educators who walk healthcare professionals through its research and product science. Hingorani's reasoning is that a doctor needs evidence before recommending anything to a patient, so the education function has to come before the sales function.
Quick commerce is the growth channel the company expects to matter most for impulse-friendly formats such as its mushroom coffee and planned fibre products, as pin-code coverage expands. That is a format question more than a marketing question: a product that fits a 10-minute delivery basket needs to be a routine purchase with a low decision cost, not a considered, expensive supplement.
What Smaller Sellers Should Copy, and What They Should Skip
The round is not a template that a shop or a small brand can copy line by line. Clinical trials with international CROs and journal publication cost far more than most sellers will ever spend on marketing in a year. But the operating discipline underneath is portable.
- Track repeat purchase by cohort and by channel. If the 90-day repeat rate is under 20 per cent, fix the product and the post-purchase experience before increasing ad spend.
- Write a specification sheet for every SKU and hold your contract manufacturer to it in writing. Ask for a certificate of analysis with each batch and keep the records.
- Test at the shelf, not just the factory. If a product has a 12-month shelf life, know what it measures at month six.
- Own a slice of your own demand. Ace Blend's website contributes about half of revenue, which means it owns the customer relationship and the data. A seller who lives entirely inside a marketplace rents both.
- Build expert recommendation slowly. A few hundred genuine recommenders, earned through evidence and training, are worth more than a discount coupon in a category built on trust.
- Match format to channel. Impulse-friendly packs suit quick commerce; considered purchases need the website and a human to answer questions.
The wider signal is that investor appetite for Indian wellness and nutrition brands has not closed, but the bar has moved. Indian Retailer noted that D2C supplement brand The Stack raised Rs 21.5 crore earlier this month, and that growing consumer interest in preventive healthcare is pulling capital into the sector. The brands attracting that capital now are the ones that can show retention, quality documentation and a defensible reason to exist beyond a label design.
For a small seller, that is the useful takeaway from a Rs 95 crore round: the things that get a nutrition brand funded are the same things that keep a smaller one alive when the ad budget runs out.
